三元生物(301206.SZ):開發高倍甜味劑是為了豐富產品矩陣,滿足客户的多樣化需求,更好地鞏固和擴大市場份額
格隆匯6月20日丨三元生物(301206.SZ)在投資者互動平台表示,高倍甜味劑與低倍甜味劑在應用上具有互補關係,而非完全的替代關係。客户選擇甜味劑組合主要基於產品需求、口感效果和成本考慮。公司開發高倍甜味劑是為了豐富產品矩陣,滿足客户的多樣化需求,更好地鞏固和擴大市場份額。此外,公司在研發新產品時,會評估市場前景和技術可行性,確保新產品符合市場需求和公司的發展戰略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.